GSA Capital Partners’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-61,819
| Closed | -$1.58M | – | 2015 |
|
|
2024
Q4 | $1.58M | Buy |
61,819
+17,284
| +39% | +$441K | 0.12% | 163 |
|
|
2024
Q3 | $1.26M | Sell |
44,535
-3,472
| -7% | -$98.2K | 0.1% | 328 |
|
|
2024
Q2 | $1.27M | Buy |
48,007
+39,966
| +497% | +$1.05M | 0.09% | 357 |
|
|
2024
Q1 | $244K | Sell |
8,041
-6,196
| -44% | -$188K | 0.02% | 1318 |
|
|
2023
Q4 | $400K | Sell |
14,237
-56,554
| -80% | -$1.59M | 0.03% | 944 |
|
|
2023
Q3 | $1.92M | Buy |
70,791
+58,012
| +454% | +$1.57M | 0.16% | 118 |
|
|
2023
Q2 | $393K | Sell |
12,779
-290
| -2% | -$8.92K | 0.04% | 889 |
|
|
2023
Q1 | $471K | Buy |
+13,069
| New | +$471K | 0.05% | 753 |
|
|
2022
Q3 | – | Sell |
-12,874
| Closed | -$541K | – | 1815 |
|
|
2022
Q2 | $541K | Buy |
+12,874
| New | +$541K | 0.08% | 449 |
|
|
2022
Q1 | – | Sell |
-7,857
| Closed | -$313K | – | 1781 |
|
|
2021
Q4 | $313K | Buy |
+7,857
| New | +$313K | 0.04% | 902 |
|
|
2021
Q3 | – | Sell |
-7,440
| Closed | -$305K | – | 1720 |
|
|
2021
Q2 | $305K | Buy |
+7,440
| New | +$305K | 0.03% | 937 |
|
|
2021
Q1 | – | Sell |
-4,700
| Closed | -$235K | – | 1433 |
|
|
2020
Q4 | $235K | Buy |
+4,700
| New | +$235K | 0.04% | 893 |
|